 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Cytomegalovirus (CMV)
| Preferred Therapy and Duration Recommendation from the U.S. Centers for Disease Control and Prevention |
CMV Retinitis |
| For full recommendations, click here |
Overview
- A Clinical Overview of Ganciclovir (Cytovene, Vitrasert) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Cytomegalovirus and HIV (May 2006)
From HIV InSite - Ophthalmic Manifestations of HIV: Cytomegalovirus Retinitis (August 2005)
A brief clinical overview.
From HIV InSite - Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents: Viral Infections (December 2004)
163 slides covering CMV, HSV, HZV, HHV-8, HPV, HCV, and HBV; available only in PowerPoint.
From AETC National Resource Center - Cytomegalovirus Retinitis in 2003 (May 2003)
Even with the advent of HAART, CMV disease continues to be an important clinical problem in people living with HIV.
In Hopkins HIV Report - Patient/Doctor Q&A: CMV, Cervical Cancer, MRSA and Low Platelets (September 2002)
To read PDF, click here
In HIV Treatment ALERTS!, from The Center for AIDS - Chart of Opportunistic Infections: Cytomegalovirus (October 2001)
From Project Inform - Eye Diagram (May 1998)
From U.S. National Institutes of Health
Prevention
- Loss of Cytomegalovirus-Specific CD4 T Cell Responses in Human Immunodeficiency Virus Type-1-Infected Patients with High CD4 T Cell Counts and Recurrent Retinitis (April 25, 2001)
In Journal of Infectious Diseases - Withdrawing Secondary CMV Prophylaxis (August 1998)
In HIV Newsline, from San Francisco General Hospital - Combination Therapy May Stave Off Further Bouts of CMV Retinitis (June 1998)
In AIDS Care, from San Francisco General Hospital
Treatment
- Cytomegalovirus Disease (December 17, 2004)
A chapter from "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents" guidelines.
To read PDF, click here
In Morbidity and Mortality Weekly Report, from U.S. Centers for Disease Control and Prevention - Valganciclovir: A New Treatment for Cytomegalovirus Retinitis (Winter 2002/2003)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - 2002 Safety Alert: Cytovene IV (Ganciclovir Sodium for Injection) (February 13, 2002)
From U.S. Food and Drug Administration - Valganciclovir Recommended for Approval (April 2001)
In What's New, from Project Inform - Approval Letter for the Use of Vitravene Injection for the Local Treatment of Cytomegalovirus (CMV) Retinitis (August 28, 1998)
From U.S. Food and Drug Administration - Better Treatment for CMV Retinitis: An Update (August 1998)
In HIV Newsline, from San Francisco General Hospital - Improved Treatment of CMV Retinitis (February 1998)
In HIV Newsline, from San Francisco General Hospital - The State of the Art: Treatment of CMV Disease (Spring 1997)
A comprehensive report.
In Direct Information on Research and Treatment Newsletter, from ARIC - New Developments in the Management of CMV Infections (April 1996)
In HIV Newsline, from San Francisco General Hospital
Research
- Literature Citations for the Diagnosis of Cytomegalovirus in HIV-Infected Patients (Regularly Updated)
From U.S. National Institutes of Health - Literature Citations for the Etiology of Cytomegalovirus in HIV-Infected Patients (Regularly Updated)
From U.S. National Institutes of Health - Literature Citations for the Treatment of Cytomegalovirus in HIV-Infected Patients (Regularly Updated)
From U.S. National Institutes of Health - CMV Levels May Predict HIV Disease Progression (October 2004)
Quick recap of a study in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS - HAART Good for Vision and Quality of Life, Studies Find (June 18, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - A Synergistic Effect of HIV and CMV Infection/Reactivation on Response to HAART and Plasma CD8+/CD38+ But Not CD4+ Cell Populations in Patients With Primary HIV Infection (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO - Oral Valganciclovir as Effective as IV Ganciclovir in Treating CMV Retinitis in AIDS Patients (April 12, 2002)
Results of a recent Emory University study.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Discontinuation of Maintenance Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients Who Have Responded to Highly Active Antiretroviral Therapy (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Loss of Cytomegalovirus-Specific CD4 T Cell Responses in Human Immunodeficiency Virus Type-1-Infected Patients With High CD4 T Cell Counts and Recurrent Retinitis (April 15, 2001)
In Journal of Infectious Diseases - Needleless Retinitis Therapy with FDA Approval of Oral CMV Drug (April 2001)
In TAGline, from Treatment Action Group - Long-Term Effects of HAART on Morbidity and Mortality in HIV-1-Infected Patients at Risk for CMV Disease (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Multicenter Evaluation of CMV Reactivation in HIV-infected Women at Potential Risk for CMV Disease (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Anti-HIV Treatment Improves Immune System and Fights Sight-Threatening Eye Infection (November 2, 1999)
From U.S. National Institutes of Health - Update: Treatment of CMV Retinitis (October 1999)
In HIV Newsline, from San Francisco General Hospital - Secondary Prophylaxis for CMV Retinitis (August 1999)
In HIV Newsline, from San Francisco General Hospital - HIV-Related Clinical Updates: CMV/Cytomegalovirus Disease (May 2, 1998)
In The 8th Clinical Care Options for HIV Symposium, from The Body PRO - Impact of Highly Active Antiretroviral Therapy on Opportunistic Infections (3 abstracts) (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - CMV: Pathogenesis, Viral Load and Prophylaxis Treatment Strategies (June 1997)
In The 7th Annual Clinical Care Options for HIV Symposium, from The Body PRO - Combination Drug Therapy for AIDS Found to Control Blinding Eye Infection (May 1997)
From U.S. National Institutes of Health - Treatment of CMV Retinitis (March 1997)
In Hopkins HIV Report, from Johns Hopkins AIDS Service - CMV Retinitis Despite High CD4 Lymphocyte Counts (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Lobucavir (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Cytomegalovirus: Report from the The Third International Conference on Drug Therapy in HIV Infection (November 1996)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care - Combination of Ganciclovir and Foscarnet Better than Monotherapy for Retinitis (April 1996)
In HIV Newsline, from San Francisco General Hospital - Cytomegalovirus Retinitis: New Approaches (March 1996)
In Moore News for Care Providers, from Johns Hopkins AIDS Service
  |
  |